Kimberlee C Drapkin Jounce Therapeutics, Inc. (JNCE) insider trading activity

Kimberlee C Drapkin is President, CFO and Treasurer of Jounce Therapeutics, Inc.. Currently has a direct ownership of 0 shares of JNCE, which is worth approximately $0. The most recent transaction as insider was on May 03, 2023, when has been sold 66,018 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Kimberlee C Drapkin Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 03 2023	SELL Disposition due to a tender of shares in a change of control transaction	-	66,018 Reduced 100.0%	0 Common Stock
Jan 10 2023	SELL Open market or private sale	$8,714 $1.12 p/Share	7,781 Reduced 10.54%	66,018 Common Stock
Jan 09 2023	SELL Open market or private sale	$6,946 $1.1 p/Share	6,315 Reduced 7.88%	73,799 Common Stock
Feb 01 2022	BUY Grant, award, or other acquisition	-	27,500 Added 25.55%	80,114 Common Stock
Jan 10 2022	SELL Open market or private sale	$54,676 $6.65 p/Share	8,222 Reduced 13.52%	52,614 Common Stock
Jan 07 2022	SELL Open market or private sale	$33,544 $7.3 p/Share	4,595 Reduced 7.02%	60,836 Common Stock
Feb 01 2021	BUY Grant, award, or other acquisition	-	22,250 Added 25.38%	65,431 Common Stock
Jan 21 2021	SELL Open market or private sale	$45,588 $12.0 p/Share	3,799 Reduced 8.09%	43,181 Common Stock
Jan 21 2021	BUY Exercise of conversion of derivative security	$8,966 $2.36 p/Share	3,799 Added 7.48%	46,980 Common Stock
Jan 20 2021	SELL Open market or private sale	$288,997 $11.03 p/Share	26,201 Reduced 37.76%	43,181 Common Stock
Jan 20 2021	BUY Exercise of conversion of derivative security	$16,066 $1.19 p/Share	13,501 Added 16.29%	69,382 Common Stock
Jan 08 2021	SELL Open market or private sale	$21,910 $7.0 p/Share	3,130 Reduced 5.3%	55,881 Common Stock
Jan 07 2021	SELL Open market or private sale	$18,232 $6.76 p/Share	2,697 Reduced 4.37%	59,011 Common Stock

Also insider at

YMTX

YUMANITY THERAPEUTICS, INC. Healthcare

ABOS

Acumen Pharmaceuticals, Inc. Healthcare

Director

GRPH

Graphite Bio, Inc. Healthcare

Director

KCD